NCT01190930 · ADVERSE EVENTS

Adverse events

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma · Source last updated 2026-05-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Up to 9 years
Other-event reporting threshold: 0%

Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The "AE Other" table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
B-ALL All patients receive induction therapy comprising intrathecal (IT) cytarabine on day 1; vincristine sulfate IV on days 1, 8, 15, and 22; dexamethasone orally (PO) or IV twice daily (BID) on days 1-28; pegaspargase IV over 1-2 hours on day 4; and IT methotrexate on days 8 and 29. Patients with DS also receive leucovorin calcium every 12 hours on days 10-11 and 21-32. Patients with Philadelphia chromosome-positive disease are eligible to transfer to COG-AALL0622 by day 15 of induction therapy and patients with high-risk (HR) or very high-risk (VHR) disease are eligible to transfer to a COG HR or VHR trial at the end of induction therapy. Patients with standard-risk disease with Down syndrome (DS) who have bone marrow minimal residual disease 0.01% are eligible to transfer to the DS stratum of the HR trial. Patients with induction failure (defined as M3 \[\> 25% lymphoblasts\] on day 29) may be eligible for the COG VHR-acute lymphoblastic leukemia study.	72 / 9229	1776 / 9229	125 / 9229
B-LLy Induction: same trt as B-ALL; Consolidation (4 wks): vincristine sulfate day 1; mercaptopurine days 1-28; IT methotrexate (MTX) days 1/8/15; leucovorin calcium days 3-4,10-11,17-18 Interim maintenance I (8 wks): vincristine sulfate and MTX 2-15 min days 1/11/21/31/41; IT MTX day 31; leucovorin calcium days 33-34 Delayed-intensification (8 wks): dexamethasone days 1-7 and 15-21; vincristine sulfate and doxorubicin hydrochloride on days 1/8/15; pegaspargase 1-2 hrs day 4; cyclophosphamide day 29; thioguanine days 29-42; cytarabine 29-32, 33-39; IT MTX days 1/29; and leucovorin calcium days 3-4, 31-32 Interim maintenance II (8 wks): vincristine sulfate and MTX days 1/11/21/31/41; IT MTX days 1/31; and leucovorin calcium days 3-4, 33/34 Maintenance: vincristine sulfate day 1; dexamethasone days 1-5; MTX weekly days 8-78; mercaptopurine days 1-84; and IT MTX day 1. Courses repeat every 4 wks for 2 yrs (from the start of IMI therapy).	0 / 48	30 / 48	2 / 48
B-ALL Average Risk Consolidation (4 wks): vincristine (VIN) day (d) 1; mercaptopurine (MP) d 1-28; IT MTX d 1/8/15; leucovorin (LV) d 3-4/10-11/17-18 Int. maint. I (8 wks): VIN and MTX d 1/11/21/31/41; IT MTX d 31; LV d 33-34 Delayed-intensification (8 wks): dexamethasone (DEX) d 1-7/15-21; VIN and doxorubicin d 1/8/15; pegaspargase d 4; cyclophosphamide d 29; thioguanine d 29-42; cytarabine d 29-32/33-39; IT MTX d 1/29; LV d 3-4/31-32 Int. maint. II (8 wks): VIN and MTX d 1/11/21/31/41; IT MTX d 1/31; LV d 3-4/33-34	16 / 3122	1037 / 3122	16 / 3122
Standard Risk With Down Syndrome Consolidation (4 w): vincristine (VIN) d1; MP d1-28; IT methotrexate (MTX) d1/8/15; leucovorin (LV) d3-4/10-11/17-18 Interim maintenance I (8 wks): VIN \& IV MTX d1/11/21/31/41; IT MTX d31; LV d36-34 Delayed-intensification (8 wks): Patients receive dexamethasone (DEX) d1-7/15-21; VIN \& doxorubicin d1/8/15; pegaspargase d4; cyclophosphamide d29; thioguanine d 29-42; cytarabine d29-32/33-39; IT MTX d1/29; and LV d3-4/31-32 Interim maintenance II (8 wks): VIN \& IV MTX d1/11/21/31/41; IT MTX d1/31; and LV d3-4/33-34 Maintenance: VIN d1; DEX d1-5; PO MTX wkly d8-78; MP d1-84; and IT MTX d1. Courses repeat every 12 wks for 2 years (timed from the start of interim maintenance I therapy).	9 / 224	191 / 224	11 / 224
B-ALL Low Risk Arm I (LR-M) Consolidation (19 w): vincristine (VIN) day(d) 15/22/78/85; IV/IT methotrexate (MTX) d8/29/50/71/92/113; leucovorin (LV) d9-10/30-31/51-52/72-73/93-94/114-115; dexamethasone (DEX) d15-21/78-84; mercaptopurine (MP) d 1-133. Maint.: VIN d1/8; DEX d1-7; MTX\* PO wkly d1-106; MP d 1-112. Repeat every 16 w until 2.5 yrs from dx. IT MTX d1/85 (course 1\&4), d 57 (course 2\&5), d29 (course 3\&6). Course 7: VIN d1/8; DEX d 1-7; MTX PO wkly d8-64; and MP d1-70. \*Patients do not receive MTX PO on d w/ IT MTX.	0 / 301	103 / 301	0 / 301
B-ALL Low Risk Arm II (LR-C) Consolidation (4 w): VIN d1; MP d1-28; IT MTX d1/8/15 Interim Maint. I (8 w): VIN \& IV MTX d1/11/21/31/41; IT MTX d31 Delayed-intensification (8 w): DEX d1-7/15-21; VIN \& doxorubicin d1/8/15; pegaspargase d4; cyclophosphamide d29; thioguanine d 29-42; cytarabine d29-32/36-39; IT MTX d1/29 Interim Maint. II (8 w): VIN \& IV MTX d1/11/21/31/41; IT MTX d1/31 Maint.: VIN d1; DEX d1-5; MTX PO wkly d22-78; MP d 1-84; IT MTX d1. Rpt every 12 w for 2 yrs:girls, 3 yrs:boys from start IM1	0 / 302	143 / 302	1 / 302
B-ALL Average Risk-Arm A Maintenance: repeat every 12 wks for 2 yrs (girls), 3 yrs (boys) from start IM1: VIN d 1/29/57; DEX d 1-5/29-33/57-61; MTX weekly d 8-78; MP d 1+P8:W8-84; and IT MTX d 1	7 / 600	180 / 600	7 / 600
B-ALL Average Risk-Arm B Maintenance: repeat every 12 wks for 2 yrs (girls), 3 yrs (boys) from start IM1: VIN d 1/29/57; DEX d 1-5/29-33/57-61; high-dose (HD) MTX weekly d 8-78; MP d 1-84; and IT MTX d 1	7 / 586	204 / 586	8 / 586
B-ALL Average Risk-Arm C Maintenance: repeat every 12 wks for 2 yrs (girls), 3 yrs (boys) from start IM1: VIN d 1; DEX d 1-5; MTX weekly d 8-78; MP d 1-84; IT MTX d 1	4 / 586	156 / 586	6 / 586
B-ALL Average Risk-Arm D Maintenance: repeat every 12 wks for 2 yrs (girls), 3 yrs (boys) from start IM1: VIN d 1; DEX d 1-5; HD MTX weekly d 8-78; MP d 1-84; IT MTX d 1	3 / 592	152 / 592	7 / 592

Group identifiers: EG000: B-ALL · EG001: B-LLy · EG002: B-ALL Average Risk · EG003: Standard Risk With Down Syndrome · EG004: B-ALL Low Risk Arm I (LR-M) · EG005: B-ALL Low Risk Arm II (LR-C) · EG006: B-ALL Average Risk-Arm A · EG007: B-ALL Average Risk-Arm B · EG008: B-ALL Average Risk-Arm C · EG009: B-ALL Average Risk-Arm D

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
9229
num Events
1
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Anemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
9229
num Events
0
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
1
num At Risk
586
num Events
1
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Blood and lymphatic system disorders - Other, specify
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
2
num At Risk
9229
num Events
2
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Disseminated intravascular coagulation
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
3
num At Risk
9229
num Events
3
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
2
num At Risk
224
num Events
2
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Febrile neutropenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
3
num At Risk
9229
num Events
3
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
1
num At Risk
3122
num Events
1
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Cardiac arrest
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
9229
num Events
1
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
1
num At Risk
3122
num Events
1
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
1
num At Risk
600
num Events
1
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Heart failure
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
9229
num Events
0
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
1
num At Risk
600
num Events
1
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Supraventricular tachycardia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
9229
num Events
0
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
1
num At Risk
3122
num Events
1
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Ventricular tachycardia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Endocrine disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
9229
num Events
0
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
1
num At Risk
224
num Events
1
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Adrenal insufficiency
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
2
num At Risk
9229
num Events
2
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Abdominal distension
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
2
num At Risk
9229
num Events
2
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Ascites
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
9229
num Events
1
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Colitis

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
26
num At Risk
9229
num Events
26
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
19
num At Risk
3122
num Events
21
group Id
EG003
num Affected
2
num At Risk
224
num Events
2
group Id
EG004
num Affected
2
num At Risk
301
num Events
2
group Id
EG005
num Affected
3
num At Risk
302
num Events
3
group Id
EG006
num Affected
2
num At Risk
600
num Events
2
group Id
EG007
num Affected
2
num At Risk
586
num Events
2
group Id
EG008
num Affected
2
num At Risk
586
num Events
2
group Id
EG009
num Affected
3
num At Risk
592
num Events
3
term
Anemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
9229
num Events
0
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
3
num At Risk
3122
num Events
3
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
1
num At Risk
301
num Events
1
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
1
num At Risk
586
num Events
1
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Blood and lymphatic system disorders - Other, specify
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
9229
num Events
1
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
1
num At Risk
586
num Events
1
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Bone marrow hypocellular
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
3
num At Risk
9229
num Events
3
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Disseminated intravascular coagulation
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
114
num At Risk
9229
num Events
114
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
101
num At Risk
3122
num Events
112
group Id
EG003
num Affected
114
num At Risk
224
num Events
185
group Id
EG004
num Affected
13
num At Risk
301
num Events
15
group Id
EG005
num Affected
14
num At Risk
302
num Events
16
group Id
EG006
num Affected
28
num At Risk
600
num Events
34
group Id
EG007
num Affected
35
num At Risk
586
num Events
40
group Id
EG008
num Affected
23
num At Risk
586
num Events
26
group Id
EG009
num Affected
27
num At Risk
592
num Events
32
term
Febrile neutropenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
9229
num Events
0
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
1
num At Risk
224
num Events
1
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Hemolytic uremic syndrome
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
6
num At Risk
9229
num Events
6
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
1
num At Risk
3122
num Events
1
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
1
num At Risk
586
num Events
1
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Cardiac arrest
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
9229
num Events
0
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
1
num At Risk
3122
num Events
1
group Id
EG003
num Affected
1
num At Risk
224
num Events
1
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Cardiac disorders - Other, specify
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
9229
num Events
1
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Heart failure
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
9229
num Events
1
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
1
num At Risk
3122
num Events
1
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
1
num At Risk
600
num Events
1
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Sinus bradycardia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
9229
num Events
1
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Sinus tachycardia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
2
num At Risk
9229
num Events
2
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Supraventricular tachycardia

Complete source fields

description

event Groups

deaths Num Affected
125
deaths Num At Risk
9229
description
All patients receive induction therapy comprising intrathecal (IT) cytarabine on day 1; vincristine sulfate IV on days 1, 8, 15, and 22; dexamethasone orally (PO) or IV twice daily (BID) on days 1-28; pegaspargase IV over 1-2 hours on day 4; and IT methotrexate on days 8 and 29. Patients with DS also receive leucovorin calcium every 12 hours on days 10-11 and 21-32. Patients with Philadelphia chromosome-positive disease are eligible to transfer to COG-AALL0622 by day 15 of induction therapy and patients with high-risk (HR) or very high-risk (VHR) disease are eligible to transfer to a COG HR or VHR trial at the end of induction therapy. Patients with standard-risk disease with Down syndrome (DS) who have bone marrow minimal residual disease 0.01% are eligible to transfer to the DS stratum of the HR trial. Patients with induction failure (defined as M3 \[\> 25% lymphoblasts\] on day 29) may be eligible for the COG VHR-acute lymphoblastic leukemia study.
id
EG000
other Num Affected
1776
other Num At Risk
9229
serious Num Affected
72
serious Num At Risk
9229
title
B-ALL
deaths Num Affected
2
deaths Num At Risk
48
description
Induction: same trt as B-ALL; Consolidation (4 wks): vincristine sulfate day 1; mercaptopurine days 1-28; IT methotrexate (MTX) days 1/8/15; leucovorin calcium days 3-4,10-11,17-18 Interim maintenance I (8 wks): vincristine sulfate and MTX 2-15 min days 1/11/21/31/41; IT MTX day 31; leucovorin calcium days 33-34 Delayed-intensification (8 wks): dexamethasone days 1-7 and 15-21; vincristine sulfate and doxorubicin hydrochloride on days 1/8/15; pegaspargase 1-2 hrs day 4; cyclophosphamide day 29; thioguanine days 29-42; cytarabine 29-32, 33-39; IT MTX days 1/29; and leucovorin calcium days 3-4, 31-32 Interim maintenance II (8 wks): vincristine sulfate and MTX days 1/11/21/31/41; IT MTX days 1/31; and leucovorin calcium days 3-4, 33/34 Maintenance: vincristine sulfate day 1; dexamethasone days 1-5; MTX weekly days 8-78; mercaptopurine days 1-84; and IT MTX day 1. Courses repeat every 4 wks for 2 yrs (from the start of IMI therapy).
id
EG001
other Num Affected
30
other Num At Risk
48
serious Num Affected
0
serious Num At Risk
48
title
B-LLy
deaths Num Affected
16
deaths Num At Risk
3122
description
Consolidation (4 wks): vincristine (VIN) day (d) 1; mercaptopurine (MP) d 1-28; IT MTX d 1/8/15; leucovorin (LV) d 3-4/10-11/17-18 Int. maint. I (8 wks): VIN and MTX d 1/11/21/31/41; IT MTX d 31; LV d 33-34 Delayed-intensification (8 wks): dexamethasone (DEX) d 1-7/15-21; VIN and doxorubicin d 1/8/15; pegaspargase d 4; cyclophosphamide d 29; thioguanine d 29-42; cytarabine d 29-32/33-39; IT MTX d 1/29; LV d 3-4/31-32 Int. maint. II (8 wks): VIN and MTX d 1/11/21/31/41; IT MTX d 1/31; LV d 3-4/33-34
id
EG002
other Num Affected
1037
other Num At Risk
3122
serious Num Affected
16
serious Num At Risk
3122
title
B-ALL Average Risk
deaths Num Affected
11
deaths Num At Risk
224
description
Consolidation (4 w): vincristine (VIN) d1; MP d1-28; IT methotrexate (MTX) d1/8/15; leucovorin (LV) d3-4/10-11/17-18 Interim maintenance I (8 wks): VIN \& IV MTX d1/11/21/31/41; IT MTX d31; LV d36-34 Delayed-intensification (8 wks): Patients receive dexamethasone (DEX) d1-7/15-21; VIN \& doxorubicin d1/8/15; pegaspargase d4; cyclophosphamide d29; thioguanine d 29-42; cytarabine d29-32/33-39; IT MTX d1/29; and LV d3-4/31-32 Interim maintenance II (8 wks): VIN \& IV MTX d1/11/21/31/41; IT MTX d1/31; and LV d3-4/33-34 Maintenance: VIN d1; DEX d1-5; PO MTX wkly d8-78; MP d1-84; and IT MTX d1. Courses repeat every 12 wks for 2 years (timed from the start of interim maintenance I therapy).
id
EG003
other Num Affected
191
other Num At Risk
224
serious Num Affected
9
serious Num At Risk
224
title
Standard Risk With Down Syndrome
deaths Num Affected
0
deaths Num At Risk
301
description
Consolidation (19 w): vincristine (VIN) day(d) 15/22/78/85; IV/IT methotrexate (MTX) d8/29/50/71/92/113; leucovorin (LV) d9-10/30-31/51-52/72-73/93-94/114-115; dexamethasone (DEX) d15-21/78-84; mercaptopurine (MP) d 1-133. Maint.: VIN d1/8; DEX d1-7; MTX\* PO wkly d1-106; MP d 1-112. Repeat every 16 w until 2.5 yrs from dx. IT MTX d1/85 (course 1\&4), d 57 (course 2\&5), d29 (course 3\&6). Course 7: VIN d1/8; DEX d 1-7; MTX PO wkly d8-64; and MP d1-70. \*Patients do not receive MTX PO on d w/ IT MTX.
id
EG004
other Num Affected
103
other Num At Risk
301
serious Num Affected
0
serious Num At Risk
301
title
B-ALL Low Risk Arm I (LR-M)
deaths Num Affected
1
deaths Num At Risk
302
description
Consolidation (4 w): VIN d1; MP d1-28; IT MTX d1/8/15 Interim Maint. I (8 w): VIN \& IV MTX d1/11/21/31/41; IT MTX d31 Delayed-intensification (8 w): DEX d1-7/15-21; VIN \& doxorubicin d1/8/15; pegaspargase d4; cyclophosphamide d29; thioguanine d 29-42; cytarabine d29-32/36-39; IT MTX d1/29 Interim Maint. II (8 w): VIN \& IV MTX d1/11/21/31/41; IT MTX d1/31 Maint.: VIN d1; DEX d1-5; MTX PO wkly d22-78; MP d 1-84; IT MTX d1. Rpt every 12 w for 2 yrs:girls, 3 yrs:boys from start IM1
id
EG005
other Num Affected
143
other Num At Risk
302
serious Num Affected
0
serious Num At Risk
302
title
B-ALL Low Risk Arm II (LR-C)
deaths Num Affected
7
deaths Num At Risk
600
description
Maintenance: repeat every 12 wks for 2 yrs (girls), 3 yrs (boys) from start IM1: VIN d 1/29/57; DEX d 1-5/29-33/57-61; MTX weekly d 8-78; MP d 1+P8:W8-84; and IT MTX d 1
id
EG006
other Num Affected
180
other Num At Risk
600
serious Num Affected
7
serious Num At Risk
600
title
B-ALL Average Risk-Arm A
deaths Num Affected
8
deaths Num At Risk
586
description
Maintenance: repeat every 12 wks for 2 yrs (girls), 3 yrs (boys) from start IM1: VIN d 1/29/57; DEX d 1-5/29-33/57-61; high-dose (HD) MTX weekly d 8-78; MP d 1-84; and IT MTX d 1
id
EG007
other Num Affected
204
other Num At Risk
586
serious Num Affected
7
serious Num At Risk
586
title
B-ALL Average Risk-Arm B
deaths Num Affected
6
deaths Num At Risk
586
description
Maintenance: repeat every 12 wks for 2 yrs (girls), 3 yrs (boys) from start IM1: VIN d 1; DEX d 1-5; MTX weekly d 8-78; MP d 1-84; IT MTX d 1
id
EG008
other Num Affected
156
other Num At Risk
586
serious Num Affected
4
serious Num At Risk
586
title
B-ALL Average Risk-Arm C
deaths Num Affected
7
deaths Num At Risk
592
description
Maintenance: repeat every 12 wks for 2 yrs (girls), 3 yrs (boys) from start IM1: VIN d 1; DEX d 1-5; HD MTX weekly d 8-78; MP d 1-84; IT MTX d 1
id
EG009
other Num Affected
152
other Num At Risk
592
serious Num Affected
3
serious Num At Risk
592
title
B-ALL Average Risk-Arm D

frequency Threshold

other Events

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
26
num At Risk
9229
num Events
26
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
19
num At Risk
3122
num Events
21
group Id
EG003
num Affected
2
num At Risk
224
num Events
2
group Id
EG004
num Affected
2
num At Risk
301
num Events
2
group Id
EG005
num Affected
3
num At Risk
302
num Events
3
group Id
EG006
num Affected
2
num At Risk
600
num Events
2
group Id
EG007
num Affected
2
num At Risk
586
num Events
2
group Id
EG008
num Affected
2
num At Risk
586
num Events
2
group Id
EG009
num Affected
3
num At Risk
592
num Events
3
term
Anemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
9229
num Events
0
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
3
num At Risk
3122
num Events
3
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
1
num At Risk
301
num Events
1
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
1
num At Risk
586
num Events
1
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Blood and lymphatic system disorders - Other, specify
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
9229
num Events
1
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
1
num At Risk
586
num Events
1
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Bone marrow hypocellular
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
3
num At Risk
9229
num Events
3
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Disseminated intravascular coagulation
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
114
num At Risk
9229
num Events
114
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
101
num At Risk
3122
num Events
112
group Id
EG003
num Affected
114
num At Risk
224
num Events
185
group Id
EG004
num Affected
13
num At Risk
301
num Events
15
group Id
EG005
num Affected
14
num At Risk
302
num Events
16
group Id
EG006
num Affected
28
num At Risk
600
num Events
34
group Id
EG007
num Affected
35
num At Risk
586
num Events
40
group Id
EG008
num Affected
23
num At Risk
586
num Events
26
group Id
EG009
num Affected
27
num At Risk
592
num Events
32
term
Febrile neutropenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
9229
num Events
0
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
1
num At Risk
224
num Events
1
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Hemolytic uremic syndrome
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
6
num At Risk
9229
num Events
6
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
1
num At Risk
3122
num Events
1
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
1
num At Risk
586
num Events
1
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Cardiac arrest
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
9229
num Events
0
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
1
num At Risk
3122
num Events
1
group Id
EG003
num Affected
1
num At Risk
224
num Events
1
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Cardiac disorders - Other, specify
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
9229
num Events
1
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Heart failure
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
9229
num Events
1
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
1
num At Risk
3122
num Events
1
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
1
num At Risk
600
num Events
1
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Sinus bradycardia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
9229
num Events
1
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Sinus tachycardia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
2
num At Risk
9229
num Events
2
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Supraventricular tachycardia

serious Events

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
9229
num Events
1
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Anemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
9229
num Events
0
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
1
num At Risk
586
num Events
1
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Blood and lymphatic system disorders - Other, specify
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
2
num At Risk
9229
num Events
2
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Disseminated intravascular coagulation
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
3
num At Risk
9229
num Events
3
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
2
num At Risk
224
num Events
2
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Febrile neutropenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
3
num At Risk
9229
num Events
3
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
1
num At Risk
3122
num Events
1
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Cardiac arrest
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
9229
num Events
1
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
1
num At Risk
3122
num Events
1
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
1
num At Risk
600
num Events
1
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Heart failure
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
9229
num Events
0
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
1
num At Risk
600
num Events
1
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Supraventricular tachycardia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
9229
num Events
0
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
1
num At Risk
3122
num Events
1
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Ventricular tachycardia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Endocrine disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
9229
num Events
0
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
1
num At Risk
224
num Events
1
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Adrenal insufficiency
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
2
num At Risk
9229
num Events
2
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Abdominal distension
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
2
num At Risk
9229
num Events
2
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Ascites
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
9229
num Events
1
group Id
EG001
num Affected
0
num At Risk
48
num Events
0
group Id
EG002
num Affected
0
num At Risk
3122
num Events
0
group Id
EG003
num Affected
0
num At Risk
224
num Events
0
group Id
EG004
num Affected
0
num At Risk
301
num Events
0
group Id
EG005
num Affected
0
num At Risk
302
num Events
0
group Id
EG006
num Affected
0
num At Risk
600
num Events
0
group Id
EG007
num Affected
0
num At Risk
586
num Events
0
group Id
EG008
num Affected
0
num At Risk
586
num Events
0
group Id
EG009
num Affected
0
num At Risk
592
num Events
0
term
Colitis

time Frame

Up to 9 years

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice